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1. Introduction 
Thyroid hormone excess due to any cause is state of thyrotoxicosis, whereas 
hyperthyroidism is a state of thyroid hormone excess due to hyperfunctioning of thyroid 
gland. The major causes of thyrotoxicosis include Graves’ disease, solitary toxic adenoma, 
and toxic multinodular goiter. In thyrotoxicosis, free hormone levels are invariably 
increased. The reverse is not true in that increased free thyroid hormone levels do not 
always point to thyrotoxicosis. In illness or resistance to thyroid hormones increased free 
hormone levels are present while the patients are clinically euthyroid or even sometimes 
hypothyroid. Subclinical thyrotoxicosis is defined as a state in which free thyroid homones 
(FT4 & FT3) are within normal limit, but serum TSH level is low. The most common cause of 
subclinical thyrotoxicosis is exogenous administration of thyroid hormone rather than 
Graves’ disease. Patients of subclinical thyrotoxicosis either have no symptoms or have mild 
non specific symptoms. 
The various causes of thyrotoxicosis are listed below in table 1 
1.1. Clinical features 
Clinical manifestations of the thyrotoxicosis are similar for various causes of thyrotoxicosis. 
However certain features provide some clues about specific cause of throtoxicosis. These 
features include the duration and mode of onset of thyrotoxicosis, size and shape of the 
thyroid gland, presence or absence of the extra-thyroidal manifestations like Graves’ eye 
sign, pre-tibial myxoedema, acropachy. Patient presenting with toxic features can be 
because of thyroiditis or Graves’ disease, but the symptoms are of few weeks duration in 
former while in later condition, it is for several months, most of the time. The common 
clinical features of thyrotoxicosis are listed below in table 2. 
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A. Thyroid hormone excess with hyperthyroidism 
a. Primary Hyperthyroidism 
i. Graves’ Disease 
ii. Toxic Thyroid adenoma 
iii. Toxic Multinodular Goiter 
iv. Metastases from Thyroid carcinoma 
v. Mutations of TSH receptor, Gsα (Mc Cune Albright Syndrome) 
vi. Struma Ovarii 
vii. Iodine ingestion (jod-Basedow phenomenon) 
b. Secondary hyperthyroidism 
i. TSH secreting pituitary tumours 
ii. Pituitary Thyroid hormone resistance 
B. Thyroid hormone excess without hyperthyroidism 
a. Throiditis: subacute, silent 
b. Ingestion of thyroid tissue, thyroid hormone  
c. Thyroid gland destruction by amiodarone, radiotherapy, infarction in 
thyroid adenoma 
Table 1. Causes of thyroid hormone excess 
Symptoms Signs
Irritability, Hyperactivity, Dysphoria Tachycardia, Lone Atrial Fibrillation  
Heat Intolerance Fine tremor 
Palpitation, Nervousness Warm moist skin, Goiter 
Fatigue, lethargy Proximal Myopathy 
Dyspnoea Hyperreflexia 
Weight loss despite polyphagia Lid lag, Lid tremors 
Hyperdefecation, Polyuria Gynaecomastia 
Oligomenorrhoea Loss of libido 
Table 2. Common clinical features 
2. Graves’ disease  
Diffuse toxic goitre is commonly known as Graves’ disease. Classically it is characterized by 
hyperthyroidism and diffuse goiter. Graves’ disease may be associated with an infiltrative 
orbitopathy and ophthalmopathy and less commonly with an infiltrative dermopathy. 
Infiltrative orbitopathy is an unique manifestation of Graves’ disease.  
2.1. Historical perspective 
Robert James Graves, an Irish physician, first described 3 females with this disease in 18351 
and for his contribution, this disease is known as Graves’ disease in most part of the world. 
Although a similar syndrome was described by Caleb Hiller Parry, a physician from Bath, 
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England, in 1825.2 Carl A. Von Basedow from Germany first described the triad of 
exophthalmos, goiter and palpitation.3 In most non English speaking European countries the 
disease is still known as Basedow’s disease.  
2.2. Epidemiology 
Graves’ disease is the most common cause of thyrotoxicosis and it accounts for 60-80% cases 
of thyrotoxicosis. Prevalence of Graves’ disease varies with the degree of iodine sufficiency, 
and it is the most common cause of thyrotoxicosis in iodine sufficient countries.4 High 
dietary iodine intake is associated with an increased prevalence of Graves’ disease. 
Prevalence of Graves’ disease is about 0.4% in USA,5 0.6% in Italy,6 and 1.1% in UK.7 A 
recent meta-analysis of various studies showed that prevalence of the Graves’ disease is 
about 1% in general population.7 Prevalence of Graves’ disease is 1-2% in women, and it is 
about 10 fold more prevalent in women than men. Peak age of onset of Graves’ disease is in 
fourth to sixth decade of life,8 but it can occur in children and elderly.  
2.3. Risk Factors for Graves’ disease 
Graves’ disease is a multifactorial disease in which genetic ,environmental, and hormonal 
factors play their role.  
2.3.1. Genetic factors for Graves’ disease 
High prevalence of Graves’ disease in family members and relatives of Graves’ disease and 
Hashimoto’s thyroiditis support that genetic factors are involved in causation of Graves’ 
disease. There is also evidence that occurrence rate of Graves’ disease is higher in 
monozygotic twins than dizygotic twins. The concordance rate in monozygotic twins is only 
17-35% which indicate low penentrance of genes.  
Graves’ disease is a polygenic disease. Polymorphism in HLA-DR, CTLA-4 and PTPN-22 
genes are associated with increased risk of Graves’ disease. HLA-DR3 (HLA-DRB1*03), 
HLA-DQA1*0501 and HLA-B8 gives a risk ratio of three fold to fourfold in white 
population. HLA-DQ3 is involved in patients with African descent whereas HLA-BW46 is 
involved in patients with Asian descent. The other genes involved in pathogenesis of 
Graves’ disease are CD40 gene, thyroglobulin gene, TSHR gene, immunoglobulin genes, 
GD-1 gene (on chromosome 14q13), GD-2 gene (on chromosome 20) and GD-3 gene (on 
chromosome Xq21-22). 
2.3.2. Environmental Factors for Graves’ disease 
Infection 
From very early it has been suggested that Graves’ disease is associated with infectious 
agents, but this hypothesis has not been confirmed. Incidence of recent viral infections are 
high in patients with Graves’ disease. The association of Graves’ disease with infectious 
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agents can be explained by molecular mimicry. Molecular mimicry implies structural 
similarity between infectious agent with a self antigen. Circulating antibody against Yersinia 
enterocolitica has been found in high percentage of patients with Graves’ disease. 
Furthermore, serum from some patients recovering from Yersinia infections block the 
binding of TSH to its receptor. Low affinity binding sites for TSH have also been found with 
Leishmania and Mycoplasma species. However, no studies proved that infections agents 
have causative role in Graves’ disease.  
Stress 
In different studies, it has been found that stressful life events precedes the onset of Graves’ 
disease. Severe emotional and physical stress, like separation from the loved one or 
following road traffic accident, cause release of cortisol ad corticotrophin releasing hormone. 
So, stress is a relatively immune suppression state. Immune system overcompensates once 
stress is over which can precipitate disease similar to postpartum period. In conclusion there 
is limited but significant evidence that stressful life events can precipitate the onset of 
Graves’ disease in genetically susceptible individuals. 
Gender 
Typically Graves’ disease is more prevalent in females than males. It is about 5-10 times 
more common in females at any age. 6,7 In children this difference is smaller. The exact cause 
for female preponderance is not known, but it is similar to other autoimmune disorders. In 
experimental animal models of autoimmune thyroiditis it has been seen that androgens 
appear to down regulate the immune system.8,9 Other possible explanation for female 
preponderance is female sex steroids. But Graves’ disease also occurs in men and 
postmenopausal women. These observations have suggested that it is the X-chromosome, 
not the sex steroids, which is responsible. But most of the x-linked disorders are only 
present in man, it has been thought that a gene with dose dependent effect on  
X-chromosome is responsible. 
Pregnancy 
Postpartum period is an important risk factor for both the onset and relapse of Graves’ 
disease. Postpartum period is associated with a fourfold to eightfold increased risk for the 
onset of Graves’ disease. Rebound immunity is the likely explanation for this increased risk. 
Graves’ disease is associated with low pregnancy rate because thyrotoxicosis decreases the 
fertility rate. However in women with Graves’ disease who became pregnant, successful 
pregnancy outcome is low because Graves’ disease causes increased pregnancy loss and its 
complications. Graves’ disease exacerbates during the first trimester of pregnancy and 
postpartum period, while it improves during the second and third trimester of pregnancy. 
Smoking 
Smoking is a minor risk factor for Graves’ disease; however it is a major risk factor for 
Graves’ ophthalmopathy. There are number of studies showing relationship between 
Graves’ disease, Graves’ ophthalmopathy and smoking. 11,12 
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Other risk factors: 
Direct trauma to the thyroid gland, ethanol injection for the treatment of autonomously 
functioning thyroid nodules, or thyroid injury following radio-iodine treatment for toxic 
adenoma or toxic multinodular goiter are associated with an increased risk of Graves’ 
disease. Radio-iodine treatment may also cause onset or worsening of ophthalmopathy. 
Possible explanation is that thyroid injury by any means cause massive release of thyroid 
antigens, which in turn stimulate an autoimmune reaction to TSHR in susceptible 
individuals. 
Graves’ disease onset and recurrence is also associated with iodine and iodine containing 
drugs like amiodarone and radio-contrast media especially in iodine deficient population. 
3. Pathogenesis 
Graves’ disease is an example of organ specific autoimmune disorder in which both 
humoral and cell mediated immunity directed against different thyroid antigens are 
involved. TSHR is the primary autoantigen of Graves’ disease, while other autoantigens like 
thyroglobulin and thyroid peroxidase are secondarily involved.  
3.1. Humoral immunity 
TSHR is a member of GPCR super family and involves cAMP and phosphoinositol 
pathways for signal transduction. TSHR has large intracellular domain (subgroup B). It is a 
glycoprotein consisting of 744 amino acids and having molecular weight of 84 kd. Gene for 
TSHR is located on chromosome 14q31 and is formed by 10 exons. Circulating autoantibody 
directed against the TSHR is the primary factor responsible for Graves’ disease. TSHR 
antibodies (TSHR-Ab) are of three types- namely stimulating antibody, blocking antibody 
and neutral antibody. Stimulating antibodies are those who after binding to TSHR activate 
adenylate cyclase and cause increased thyroid growth and vascularity, and increases the 
production of thyroid hormones. Blocking antibodies are those who after binding to TSHR 
act as an antagonist, whereas neutral antibodies does not have any functional activity. 
Almost 50 years ago(in 1956) long acting thyroid stimulators (LATS) was discovered by 
Adams and Purves during a search for thyroid stimulating activity in patients with Graves' 
disease. 13 Later on it was found that LATS are nothing but immunoglobulin of IgG1 
subclass. 
Transplacental transfer of TSHR stimulating antibodies (TSAb) from TSAb positive 
pregnant mother to fetus causes transient neonatal thyrotoxicasis that improves 
spontaneously after the disappearance of TSAb. 14 This provides the definite role of TSAb in 
the causation of Graves' disease. TSAb are oligoclonal.  
TSAb are produced mainly by the lymphocytes infiltrating the thyroid gland and 
lymphocytes present in the draining lymph nodes, and partly by the circulating blood 
lymphocytes.15,16 There is a positive correlation exists between the TSAb level and serum 
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triiodothyronine level, serum thyroglobulin level and goiter size. TSAb are found in 90-
100% of untreated Graves' disease patients.17, 18 Level of TSAb decreases after treatment with 
anti- thyroid drugs and radio-iodine.19, 20 
3.2. Assays for TSHR-Ab 
Two types of assays are used for TSHR-Ab-Radioreceptor assays and invitro bioassays. 
3.2.1. Radioreceptor assay 
Radioreceptor assay is most readily available and most widely used in clinical practice. Basic 
principle of radioreceptor assay is displacement of labeled TSH from solubilized TSHR from 
patient's serum. This TSH- binding inhibitory immunoglobulins (TBII) assay does not provide 
information regarding the functionality of TSHR-Ab. TBII assays are cheaper and having good 
precision. The first generation TBII assays have sensitivity of 75-95% in untreated Graves' 
disease patients. Most recently a monoclonal human antibody to TSHR is used. This second 
generation radio-receptor assay has sensitivity of 99% and very high specificity. 21 
3.2.2. In vitro bioassays 
In vitro bioassays are based on the ability of patients serum to stimulate adenylate cyclase 
and produce cAMP from cultured hamster ovary cells transfected with human TSHR (CHO-
R),23 or rat thyroid cell strain (FRTL-5)24 or human thyroid follicular cells 25 are used as a 
source for functional TSHR. CHO-R system is slightly more sensitive, and requires an easier 
culture condition than other systems. Advantages of bioassays are that it gives information 
about the functional property of TSHR-Ab, but bioassays are more expensive, not widely 
available, having poor precision and sensitivity of more than 90%. These problems have 
been solved in newer bioassays. 
3.2.3. Cellular immunity 
The thyroid gland in Graves' disease is characterized by non-homogenous lymphocytic 
infiltration. Majority of the intrathyroidal lymphocytes are T lymphocytes. B-lymphocytes 
are much less common than Hashimoto's thyroiditis. Cytokine profile produced by 
intrathyroidal T lymphocytes suggested that both TH1 & TH2 cells are present in thyroid. 
Majority of the T-lymphocytes are of TH1 subtype.26,27 
TH1 cells are mainly involved in delayed type of hypersensitivity reactions, and it produces 
the cytokines like TNF-B, IFN-Y, IL-2, IL-10 and IL-17. TH1 cells are implicated in the 
pathogenesis of organ specific autoimmune diseases that is mediated mainly by TNF-β 
subtype, which uniquely produces IL-17. TH 2 cells are mainly responsible for humoral 
immune responses and they produce cytokines like IL-4, IL-5, IL-6 and IL-13.TH1 cells may 
also induce antibody formation through secretion of IL-10 28. IgG1 subclass of antibody are 
selectively induced by TH1 cells. Most of the intrathyroidal T cells are of memory (CD4+, 
CD29+) subtype. Concentration of cytotoxic T cells (CD8+) are much less in Graves' disease 
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patients than patients of Hashimoto's thyroiditis. So the functional role of T cells in Graves' 
disease is primarily a helper than a suppressor or cytotoxic role. 
4. Pathogenic mechanisms 
4.1. Molecular mimicry or specificity crossover 
Structural or conformational similarity between different antigens like infectious agent with 
a self antigen can lead to crossover of specificity or molecular mimicry. Molecular mimicry 
has been reported between Reoviral antigen and a tissue antigen expressed in multiple 
endocrine tissues, Yersinia enterocolitica and TSHR, Retroviral sequences and TSHR & 
Borrelia and TSHR. 
4.2. Bystander effect 
There is evidence that bystander activation of local resident antigen specific and nonspecific 
T- cells by a local viral infection would induce an inflammatory reaction and stimulates the 
production of cytokines induce autoimmunity. This bystander activation can also occur in 
any infections and antigens unrelated to the thyroid gland.  
4.3. Aberrant expression of class II HLA Antigens 
MHC class II molecules (HLA-DP, DQ, and DR) are not expressed on the normal thyroid 
epithelial cells but they are expressed on thyroid epithelial cells in patients of autoimmune 
thyroid disease. This aberrant expression of class II HLA antigens on thyroid epithelia cells 
can be induced by local thyroid insult which causes production of interferon γ and other 
cytokines. Interferon γ is able to over express HLA class I molecule and induce the 
expression of class II molecule on thyroid epithelial cells. 
4.4. Cryptic antigens 
Autoimmunity results from the loss of tolerance or the ability to differentiate between self and 
non self. Tolerance induction is a staged process that initiates in the thymus during T-cell 
maturation. This process depends in part on the presence of peripheral antigens in the thymus. 
Peripheral antigens are antigens normally expressed in tissues outside of the immune system 
which are expressed at low levels in thymus. T cells that react strongly to these peripheral 
molecules in the context of MHC are deleted in thymus. T cells that react with peripheral 
antigens that are not expressed in the thymus have a greater opportunity to escape tolerance.  
4.5. Hygiene hypothesis 
Hygiene hypothesis implies that infection may protect form autoimmune diseases rather 
than precipitating it. Decreased exposure to antigens due to improved living standards can 
lead to increased risk of autoimmune disorder. 
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4.6. Super antigens 
Super antigens are endogenous or exogenous proteins such as microbial proteins, capable of 
stimulating a strong immune response through molecular interactions with non-variant 
parts of the T- cell repertoire and the HLA class II proteins. 
5. Pathology 
Grossly the thyroid gland is diffusely enlarged with smooth and hyperemic surface. Rarely 
the gland is grossly nodular. Consistency of the gland varies from soft to firm. Pyramidal 
lobe is often prominent. 
Microscopically both hypertrophy and hyperplasia are seen. Follicles are small with scanty 
colloid, and lined by hyperplasic columnar epithelium which can give a pseudopapillary 
appearance. Vascularity of the gland is increased. There is varying degree of infiltration by 
lymphocytes and plasma cells. T cells predominate in the interstitium, whereas B cells and 
plasma cells predominate in lymphoid follicles. 
On electron microscopy there is increased golgi reticulum and mitochondria, and it is also 
characterized by presence of prominent microvilli. 
After treatment with antithyroid drugs and radioiodine, the vascularity of the gland 
decreases, follicles enlarges and filled with colloid, and papillary projection regresses. 
6. Clinical features 
Graves' disease is the most common cause of thyrotoxicosis. Most common age of onset is 
third to fourth decade of life but it can occur in children and elderly. The hallmark of 
Graves' disease is signs and symptoms of thyrotoxicosis along with diffuse goiter and 
typical Graves' orbitopathy. Most of the signs and symptoms are similar to other causes of 
thyrotoxicosis, but some of the signs and symptoms like orbitopathy, dermopathy or 
pretibial myxedema and thyroid acropachy are unique to Graves' disease. 
Onset of Graves' disease is usually gradual. Signs and symptoms are presents months before 
the diagnosis, and usually patients do not remember the exact date of onset of symptoms. 
Onset can be abrupt in some cases. The signs and symptoms are usually more severe than 
other causes of thyrotoxicosis. 
6.1. Thyroid gland 
Thyroid gland is diffusely enlarged in Graves' disease, but it can be nodular especially in 
areas of iodine deficiency where nodular goiter preexists before the onset of Graves' disease. 
Goiter size is variable. It can range from normal size thyroid gland to massively enlarged 
thyroid. Usually size of goiter is two to three times that of normal. Normal size thyroid 
gland can the seen in as many as 20% of patients and most of them are elderly. The 
consistency of the goiter varies from soft to firm but softer than the goiter of Hashimoto's 
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thyroiditis. Thrill and bruit can be present over goiter in severe cases and it is due to 
increased vascularity of the gland. Thrill and bruit are present usually on upper or lower 
pole and continuos in nature, but sometimes can present only in systole. Large goiter with 
intrathoracic extension can be associated with facial swelling and flushing, and neck vein 
distension upon raising the arm above the head. This is known as Pemberton sign. 
6.2. Graves’ ophthalmopathy 
Graves' ophthalmopathy is one of the distinctive manifestations of Graves’ disease. Overall 
clinical ophthalmopathy is present in about 50% of Graves’ disease patients,29 however CT 
or MRI reveals extraocular muscle enlargement in about 70% of patients without overt 
clinical ophthamopathy.30,31 Bimodal age distribution was noted for ophthalmopathy in both 
men and women. Peak age is 40 to 44 years and 60 to 64 years in women, whereas in men it 
is 45 to 49 years and 65 to 69 years. 
6.2.1. Risk factors for Graves' ophthalmopathy 
There is no specific genetic predisposition for graves' ophthalmopathy. Environmental 
factors are more important for ophthalmopathy. 
Smoking 
Smoking is a major risk factor for ophthalmopathy. Smoking also increases the risk for 
worsening of ophthalmopathy after radioiodine treatment. Possible contributors are orbital 
hypoxia and free radical present is smoke. 32,33 
Gender 
Graves’ disease is predominantly a disease of females (F: M= 8-10:1). In comparison to 
Graves’ disease, ophthalmopathy is relatively more common in males (F: M= 1:1.8-2.8) than 
females. 34,35 
Radioiodine 
Graves' disease patients treated with radioiodine are at increased risk for onset and 
worsening of eye disease, as compared to antithyroid drugs alone. 36,37 This risk can be 
decreased by concurrent use of corticosterodis.38,39 
6.2.2. Pathogenesis 
Current evidence support an autoimmune pathogenesis with important environmental 
influences, particularly smoking. Orbital muscles, connective tissues, and adipose tissues are 
infiltrated by lymphocytes and macrophages. TH1 mediated immune response 
predominates in early stage of disease while TH2 response predominates in late stage. 40 In 
response to cytokines secreted by the infiltrating immune cells, orbital fibroblasts start 
synthesizing and secreting hydrophilic glycosaminoglycans, resulting in edema of orbital 
 
Thyroid Hormone 168 
tissues. Additionally adipocytes present in orbit become active and results in expansion of 
orbital adipose tissues. Both these factors are responsible for expansion of orbital tissues.  
6.2.3. Natural history 
Onset of eye disease usually coincides with that of thyrotoxicosis in 40% of cases, follow it in 
40%, and precedes it in 20%.41,42 Even when the onset of the two disorders does not coincide, 
each occurs within 18 months from the onset of the first manifestation. Eye disease usually 
shows a progressive deterioration lasting for several months followed by a phase of 
spontaneous improvement lasting upto a year and longer and quiescent stage when 
inflammatory signs disappear and clinical features stabilizes. 
6.2.4. Sings and symptoms 
The earliest manifestations of ophthalmopathy are usually a sensation of grittiness, eye 
discomfort, and excess tearing. Other common symptoms are spontaneous retroorbital pain, 
pain on ocular movement and diplopia. Diplopia is most common in upgaze or in extremes 
of lateral gaze, because of the involvement of inferior or lateral rectus muscle. About one 
third of patients have proptosis which can best be detected by visualization of the sclera 
between the lower border of iris and the lower eyelid when the eyes are kept in primary 
position. 
In severe cases proptosis can cause exposure keratitis and corneal ulcerations. Proptosis is 
frequently assymetrical. Retraction of the upper eyelid and less commonly of lower eyelid 
results in lid lag, globe lag, and lagophthalmos. Movements of the lids are jerky, and also 
there is tremor of lightly closed eyes. These are the non specific manifestations of 
thyrotoxicosis. Other signs and symptoms are photophobia, swelling of the eyelids, blurring 
of vision, conjunctival injection and chemosis, periorbital edema. 
Decreased visual acuity and color vision, corneal ulceration, and subluxation of globe are 
present in most severe cases. Blindness may result from corneal ulceration and compression 
of the optic nerve at the orbital apex due to increased orbital pressure and venous 
congestion. 
Graves' ophthalmopathy can occur in absence of Graves' disease in 10% cases, that’s why it 
is also known as thyroid associated ophthalmopathy, or euthyroid Graves’ opthalmopathy. 
Graves' ophthalmopathy is usually bilateral but it can be unilateral in upto 10% cases.  
6.2.5. Staging severity of ophthalmopathy 
The acronym NO SPECS was given by American Thyroid Association for severity of 
ophthalmopathy, where no indicates absence or mild ophthalmopathy, and SPECS indicates 
more severe degree of involvement, but NO SPECS scheme is inadequate and patients do 
not necessarily progress from one class to other. 
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Classes  Ocular symptoms and signs
0 No signs and symptoms  
1 Only signs (lid retraction, lid lag, proptosis upto 22 mm) 
2 Soft tissue involvement (periorbital edema) 
3 Proptosis (>22 mm) 
4 Extraocular muscle involvement (diplopia) 
5 Corneal involvement  
6 Sight loss (optic nerve involvement)  
Table 3.  
6.2.6. Clinical activity of ophthalmopathy 
To know the clinical activity of ophthalmopathy is important, because active disease is more 
likely to respond to immunosuppressive therapy. Clinical Activity Score (CAS) is used to 
know the clinical activity. Seven parameters are used in the clinical activity scoring which 
include spontaneous retrobulbar pain, pain on eye movement, eyelid erythema, conjuctival 
injection, swelling of the eyelids, inflammation of the caruncle and conjunctival edema or 
chemosis. Each parameter is assigned 1 point. CAS of more than or equal to 3/7 indicates 
active ophthalmopathy.  
6.3. Thyroid dermopathy 
Thyroid dermopathy presents in less than 5% of patients with Graves’ disease. It is almost 
always accompanied by moderate to severe ophthalmopathy. Most commonly it is present 
over anterior and lateral aspects of leg, hence it is also known as pretibial myxoedema. Less 
commonly it can present over dorsa of the feet, dorsa of the hands, forearm, face and 
elbows, particularly after trauma. The typical lesion is a noninflamed, indurated plaque 
with a deep pink or purple color and an orange skin appearance. Nodular form is the 
intermediate while elephantiasis is the most severe form of thyroid dermopathy. Thyroid 
dermopathy occurs due to accumulation of glycosaminoglycans in the dermis and 
subcutaneous tissues.  
6.4. Thyroid acropachy 
Thyroid acropachy is the least common manifestation of Graves' disease. It is a form of 
clubbing, and presents in less than 1 percent of patients of Graves' disease. It is almost 
always associated with the severe and long standing ophthalmopathy and dermopathy. 
An alternate diagnosis should be considered in the absence of ophthalmopathy and 
dermopathy. Deposition of glycosaminoglycans in skin is responsible for thyroid 
acropachy.  
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7. Laboratory diagnosis 
Diagnosis of Graves' disease can be confirmed by measurement of serum TSH and total 
thyroxine (TT4) and triiodothyronine (TT3). Serum TSH level is suppressed or undetectable 
with increased TT4 and TT3 level in patients of Graves' disease. Serum TSH level is the most 
sensitive test. The free T4 (FT4) and free T3 (FT3) levels are increased more than that of TT4 
and TT3. Measurement of FT4 and FT3 are expensive, and there is more chance of laboratory 
errors. FT4 and FT3 can be measured in conditions associated with high serum TBG level like 
pregnancy, oral contraceptive use and chronic liver disease. In patients of Graves' disease 
serum T3 level is proportionately more elevated than the serum T4 level. In upto 12% of 
patients, especially in the iodine deficient areas, only TT3 or FT3 is elevated with a normal 
TT4 or FT4 level, a condition known as T3 toxicosis. Conversely in some patients (iodine 
induced hyperthyroidism, drugs like amiodarone and propronolol which block the 
conversion of T4 to T3), only TT4 or FT4 is elevated with normal TT3 and FT3 (T4 toxicosis). 
Serum thyroglobulin level is high in all cases of thyrotoxicosis except factitious 
thyrotoxicosis.  
Anti TPO antibody can be detected in upto 90%43,44 of patients with Graves' disease 
whereas anti-thyroglobulin antibody is present in 50-80% cases.45,46 They are useful in 
confirming the presence of thyroid autoimmunity but they are of limited diagnostic value. 
TSHR-Ab assay is very sensitive and specific (upto 98%) for the diagnosis of Graves' 
disease. But TSHR-Ab assay is quite expensive and not widely available. TSHR-Ab assay 
is indicated only when clinical and laboratory diagnosis are not clear. Indications for 
TSHR-Ab assay are:  
 Euthyroid Graves' disease, especially when it is unilateral  
 Pregnant women with Graves' disease to predict the likelihood of neonatal 
thyrotoxicosis  
 Nodular variant of Graves' disease 
TSHR-Ab assay is also a useful indicator of the degree of disease activity. It can also predict 
the prognosis of Graves' disease. There is more chance of relapse in patients with 
persistently high TSHR-Ab level after cessation of antithyroid drug.47  
Associated hematological abnormalities include increased RBC mass, leucopenia with 
relative lymphocytosis, monocytosis and eosinophilia, increased factor VIII level. Other 
associated abnormalities include elevated liver enzymes, bilirubin and ferritin.  
7.1. Radioactive iodine uptake (RAIU) 
RAIU is not required in each and every case of Graves' disease, but it is useful in excluding 
thyrotoxicosis caused by thyroiditis, factitious thyrotoxicosis, and type II amiodarone 
induces thyrotoxicosis. RAIU is absolutely contraindicated in pregnancy. In Graves' disease 
RAIU is diffusely increased.  
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7.2. Thyroid ultrasound 
In Graves' disease thyroid tissue typically become hypoechoic because of reduction in 
colloid content, increase in thyroid vascularity and lymhocytic infiltration. In colour flow 
doppler there is a distinct pattern characterized by markedly increased signals, inferior 
thyroid artery and itrathyroidal artery velocities more than 40 cm/s. This pattern, in 
conjunction with a hypoechoic pattern allows distinction from Hashimoto's thyroiditis.  
7.3. Differential diagnosis 
If a patient presented with diffuse goiter with clinical and biochemical thyrotoxicosis, 
ophthalmopathy and positive autoimmune markers like anti TPO antibody or TSHR-Ab, 
diagnosis of Graves' disease is straight forward. In absence of these classical features 
radionuclide scan (I123, I131, Tc99m) in the most reliable distinguishing test. In case of Graves' 
disease there is diffuse and high uptake, whereas in patients with toxic adenoma or toxic 
multinodular goiter there is patchy uptake. In patients with thyroiditis and factitious 
thyrotoxicosis there is decreased uptake. In patients with TSH producing adenoma, there is 
also a diffuse goiter, but TSH is inappropriately normal or increased instead of suppress 
TSH of graves' disease. Panic attacks, mania, pheochromocytoma and malignancy can be 
easily ruled out by thyroid function test.  
8. Treatment 
There is no ideal treatment option present targeting the basic pathogenic mechanisms of 
Graves' disease. Available treatment options target the increased synthesis of thyroid 
hormones by antithyroid drugs, or ablation of thyroid tissue by surgery or radioiodine. 
Antithyroid drugs are the predominant therapy in Europe and Japan whereas radioiodine is 
first line of treatment in USA. No single treatment is optimal and patients often require 
multiple treatment.  
8.1. Antithyroid drugs 
Thionamides are the main antithyroid drugs which includes propylthiouracil, carbimazole 
and methimazole. Thionamides act by inhibiting the enzyme thyroid peroxidase, reducing 
the oxidation and organification of iodide and coupling of iodotyrosines. Carbimazole is not 
an active drug, and in body it is converted to active metabolite methimazole. 
Proylthiouracil, in addition to inhibit thyroid hormone synthesis, also inhibits the peripheral 
conversion of T4 to T3. Methimazole is ten times more potent than prophylthiouracil. Half 
life of methimazole is about 6 hours while that of prophylthiouracil is about 90 minutes. 
Duration of action of methimazole is more than 24 hours while that of propylthiouracil is 12-
24 hours. Transplacental transfer of prophylthiouracil is lowest. Antithyroid drugs do not 
block the release of preformed hormones, so euthyroidism is not obtained until 
intrathyroidal hormone store is depleted. These drugs also reduce thyroid antibody level. 
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Antithyroid drugs can be used as a primary treatment or as a preparatory treatment before 
radioiodine or surgery. The antithyroid drugs are usually started in higher doses. The 
starting dose of methiomazole or carbimazole is 10-20 mg every 8-12 hours and that of 
propylthiouracil is 100-200 mg every 6-8 hours. Once euthyroidism is achieved which 
usually takes 4-5 weeks, methimazole can be given in single daily dose while 
propylthiouracil is given in multiple daily doses throughout the treatment. There are two 
treatment strategies for using antithyroid drugs. In titration regimen, antithyroid drugs are 
started in high doses and dose can be gradually decreased to maintain euthyroid state. In 
Block and Replace regimen, the antithyroid drugs are maintained in high doses and 
subsequently levothyroxine is added to maintain the euthyroid status. At present there is no 
proven advantage of block and replace regimen over titration regimen.  
Patient should be reviewed clinically and biochemically after every 3-4 weeks. Dose of 
antithyroid drugs is adjusted based on the TT4 or FT4 level, as TSH level often remain 
suppressed for several months. The usual daily maintenance dose of carbimazole or 
methimazole is 2.5 – 10 mg and that of propylthiouracil is 50-100 mg. When TSH level 
become normal, it can also be used to monitor therapy. Size of the goiter decreases in about 
30-50% of patients during treatment. In remaining patients it may remain unchanged or 
even enlarge. Increase in goiter size is one of the earliest manifestations of iatrogenic 
hypothyroidism. The other features are weight gain, lethargy, fatigue and other signs of 
mild hypothyroidism.  
Maximum remission rate with antithyroid drugs is 30-50%, which can be achieved by 
continuation of the drug for 6-18 months or even longer. Most of the relapses occur within 
first 3-6 months after discontinuation of drug. Suppressed TSH level below the normal limit 
is the first signal of relapse even in the presence of a normal serum T4 level. In most of the 
studies, the relapse rate is 50-80%.48,49 Most important predictor of relapse is goiter size.50 
Other factors influencing recurrence of Graves' disease include high TSHR-Ab 
concentration, large iodine intake, marked residual goiter, short duration of antithyroid 
drug treatment and previous recurrence. Factors which favor long term remission after 
therapy include the initial presence of T3 toxicosis, a small goiter, decrease in the size of 
goiter, and return of TSH to normal during treatment, the return of serum thyroglobulin to 
normal, and low iodine diet.  
Most common side effects of thionamides are pruritus, skin rash, urticaria, fever and 
arthralgia. These may resolve spontaneously or after substituting another drug. Rare but major 
side effects are hepatitis, cholestasis, SLE like syndrome, ANCA positive vasculitis and most 
importantly agranulocytosis. Major side effects occur in less than 1% of patients.Antithyroid 
drugs should be stopped and not restarted if patient develop major side effects.  
8.2. Iodine and iodine containing components 
Inorganic iodine acts in many ways in thyrotoxicosis. Iodine blocks its own transport in 
thyroid, inhibits iodine organification and inhibits the release of hormone. Inhibition of 
iodine organification by inorganic iodide is known as Wolf-Chaikoff effect. Major action of 
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iodine is inhibition of hormone release. Iodine also decreases the vascularity of thyroid 
gland. All of these effects of iodine are transient and lasts only for a few days or weeks. Now 
a days iodine is used only for preoperative preparation for Graves’ disease and in the 
management of thyrotoxic crisis. The usual dose of Lugol's solution is 3-5 drops three times 
per day and that of SSKI is 2-3 drops twice daily. Iodine decreases the effect of subsequently 
administad thionamides and radioiodine for severe weeks. 
Iodinated radio contrast agents like iopanoic acid, and sodium ipodate acts by blocking the 
peripheral conversion of T4 to T3 and inhibition of hormone release. They are ideally used 
in emergency situations when rapid control of thyrotoxicosis is needed or in preoperative 
preparation or while awaiting the response of radioiodine. 
8.3. Thiocyanate and perchlorate 
They act by intititing the transport of iodine to thyroid gland. 
8.4. Lithium 
Lithium also acts as a thyroid constipating agent (block the release of thyroid hormones). 
Lithium also potentiates the beneficial effect of radioiodine. The usual dose of lithium is 450-
900 mg per day in divided doses. Serum lithium concentration should be maintained at 
1meEq/L. No adverse effects are reported with this dose of lithium. 
8.5. Glucocorticoids 
Dexamethasone in high doses (8mg/day) decreases the T4 secretion by the thyroid gland, 
inhibit the peripheral conversion of T4 to T3, and has immunosuppressive effect. Effect on 
peripheral conversion of T4 to T3 is additive to propylthiouracil. Glucocorticaids are 
indicated for the treatment of ophthalmopathy, dermopathy and in thyrotoxic crisis.  
8.6. β- blockers 
β- blockers do not affect the synthesis or secretion of thyroid hormones. Many of the 
symptoms & signs of thyrotoxicosis are due to hypersensitivity of the sympathetic nervous 
system to thyroid hormones. Thus use of β- blockers in thyrotoxicosis, improve the signs 
and symptoms mediated by the sympathetic nervous system. Tachycardia, palpitation, 
tremor, anxiety, excess sweating, lid retraction improves with β- blockers. Propranolol has 
additional advantage over other β- blockers. It inhibits the peripheral conversion of T4 to T3. 
β- blockers reduce cardiac output without altering oxygen consumption, can have adverse 
effect in liver, where the arteriovenous oxygen difference is already elevated in the 
hyperthyroid state. Propranolol is most commonly used agent but other β- blockers can also 
be used. It is used in a dose of 20-60 mg every 6-8 hours. Short acting agents like esmolol is 
used for intravenous purpose. Long acting agents like atenolol or metoprolol are used for 
prolonged treatment. β- blockers should be rapidly tapered and discontinued once stable 
euthyroidism it achieved.  
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8.7. Radioiodine 
Radioiodine is one of the first line therapy for the Graves' disease. Among different isotopes 
of radioiodine, I131 is the agent of choice. I131 is a β-emitter isotope. After oral administration, 
I131is completely absorbed and rapidly concentrated in thyroid follicular cells. β- particles, 
which are emitted by I131, destroy the thyroid follicular cells that results in reduced thyroid 
hormone synthesis. Initially destruction of thyroid follicular cells results in release of 
preformed hormones that can precipitate the thyortoxic crisis. Weeks to months are required 
for control of thyrotoxicosis. Long term effects of radioiodine include atrophy and fibrosis, 
and a chromic inflammatory response resembling Hashimoto's thyroiditis.  
Radioiodine is given as single oral dose. Three outcomes of radioiodine treatment are 
possible- patients become euthyroid or remain thyrotoxic or become permanently 
hypothyroid. Dose of radioiodine depends on the size of gland, the uptake of I131 and its 
subsequent rate of release. Dose of radioiodine ranges from 80-200 Ci/gm of thyroid 
tissues. A total dose of 20 mCi achieves thyroid ablation in almost all patients and results in 
permanent hypothyroidisms in 75-90% of patients. 51 The incidence of post radioiodine 
hypothyroidism in first year is 25% and steadily increases thereafter at a rate of 5% per year. 
When required, the second dose of radioiodine should be given at least 6 months after the 
first dose. Failure of radioiodine treatment is more common in patients with large goiter, 
rapid iodine turnover and adjunctive antithyroid drugs too soon after radioiodine. Prior use 
of antithyorid drugs decreases the risk of thyrotoxic crisis. Chance of worsening 
ophthalmopathy can also be reduced by antithyroid drugs. Antithyroid drugs should be 
stopped 3 to 8 days prior to radioiodine treatment and should be restarted after 7 days when 
required. Propylthiouracil may cause radio-resistance, but it not a major concern. Short term 
side effects of radioiodine include transient exacerbation of thyrotoxicosis in the first few 
months, transient worsening of ophthalompathy, acute radiation thyroids in the first week. 
Radiation thyroidits may lead to transient worsening of thyrotoxicosis and ophthalmopathy. 
Presence of mild to moderate ophthalmopathy is not a contraindication for radioiodine 
treatment. Concomitant use of oral glucocorticoids, decreases the risk of worsening 
ophthalmopathy. Long term side effect of radioiodine is permanent hypothyroidism. Initially 
there was a concern regarding possible carcinogenic effect and risk of genetic damage after 
radioiodine treatment. But now it is proven that there is no association between radioiodine 
treatment and thyroid carcinoma, leukemia, solid tumors and genetic damage.52 Thyroid 
cancer is associated with low dose of I131 rather than higher dose of I131 in children. 53 Some 
centers uses radioiodine even in children of 10 years of age or younger, but still there is no 
consensus regarding use of radioiodine for persons younger than 16 to 18 years. 
8.8. Surgery 
Surgery is a form of ablative therapy. Enough thyroid tissue is removed by surgery to reduce 
the synthesis of thyroid hormones and prevent recurrence. Two type of thyoid surgery are 
used for Graves' disease. In subtotal thyroidectomy, bulk of the thyroid gland is removed and 
only about 2 gm (0.5%) of thyroid tissue is left in both lobes. In near total thyroidectomy, most 
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of the thyroid gland is removed, with only subcentimeter fragment are left around recurrent 
laryngeal nerve and parathyroid glands. Subtotal thyroidectomy was the procedure of choice 
in past, but it is associated with higher recurrence rate. Now-a-days near total thyroidectomy 
is used most often. Near total thyroidectomy is associated with more chance of permanent 
hypothyroidism but less chance of recurrence than subtotal thyroidectomy. 
Complications of thyroid surgery depends on the skill and experience of operating surgeon. 
In specialized hands, complication rate is as low as 2%, whereas complication rate increases 
up to 10-15% in non specialized centers. Post Operative bleeding is the most serious 
complication. It can be fatal by producing asphyxia, if it is not evacuated immediately. Other 
complications like thyroid storm, injury to recurrent laryngeal nerve and 
hypoparathyroidism are specific to thyroid surgery. Thyroid storm is rare now-a-days. 
Injury to recurrent laryngeal nerve causes dysphonia, that usually improves with time, but 
that may leave the patient slightly hoarse. Hypoparathyroidism can be transient or 
permanent. Transient hypoparathyroidism is due to removal of the some parathyroid and 
impairment of blood supply to parathyroid glands, whereas permanent 
hypoparathyroidism is due to inadvertent removal of all 4 glands. Transient 
hypoparathyroidism usually occur on day 1-7 postoperatively. Severe symptomatic 
hypoparathyroidism should be treated by intravenous calcium gluconate. Oral calcium 
(upto 3 gm/day) is sufficient for milder cases. Immediate postoperative hypocalcemia is due 
to hungry bone syndrome. Recurrence of hyperthyroidism and permanent hypothyroidism 
are inversely related and depends on the amount of thyroid tissue left. In case of recurrence, 
radioiodine should be used as treatment, as second surgery is technically difficult.  
Preoperative preparation 
Preoperative use of thionamides is associated with lesser morbidity and mortality. 
Preoperative thionamides are recommended to achieve euthyroidism and to deplete. The 
hormone store. Preoperative use of inorganic iodine decreases the gland size and 
vcascularity. In case of emergency surgery oral cholecystographic agents are the fastest way 
to obtain euthyroidism. The goal of preoperative management is to maintain euthyroid 
states by thionamides and then to induce involution of the gland by the inorganic iodine. β 
blockers can be used in preoperative preparation. 
Choice of therapy 
Choice of therapy depends on the patient preference, personal experience of the treating 
doctor and availability of the treatment options. All the three treatment options (antithyroid 
drugs, radioiodine, surgery) can be used as first line therapy. In most of the Europe, 
antithyroid drugs are the preferred treatment whereas in USA, radioiodine is the preferred 
treatment. Primary choice of treatment in children and young adults upto 18 years of age is 
antithyroid drugs, although radioiodine is not associated with any adverse events. 
Pregnancy should be delayed for 6-12 months after radioiodine treatment. Presence of 
severe ophthalmopathy is a contraindication for radioiodine treatment. Surgery is the 
preferred treatment for patients with large goiter, especially if compressive symptoms are 
present, endemic goiter with multiple cold nodules, and suspected malignancy.  
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Thyroid ophthalmopathy 
Mild to moderate ophthalmopathy does not require any specific treatment. General 
measures include control of thyrotoxicosis, smoking cessation, dark glasses with side frame 
for photophobia and sensitivity to air, artificial tear (1% methyl cellulose) or eye ointment 
for eye discomfort and dry eye, eye patches or taping during sleep for lagophthalmos, 
elevation of the head end for periorbital edema, prism for correction of mild diplopia.  
Other patients with more severe signs and symptoms affecting daily lives to a significant 
extent may benefit from immunosuppressive therapy in active disease or surgical 
decompression in case of inactive disease. Severe ophthalmopathy with optic neuropathy 
and corneal ulcer is an emergency. 
Glucocorticoids 
Oral glucocorticoids is initiated at a relatively high dose, such as 40-80 mg of prednisolone 
per day. After 2-4 weeks, the daily dose is tapered by 2.5-10 mg every 2-4 weeks. 
Improvement in soft tissue inflammation begins within 1-2 days. Intravenous 
methylprednisolone pulse therapy is more effective and better tolerated than oral 
prednisolone.54 500 mg of methylprednisolone per week for 6 weeks followed by 250 mg of 
methylprednisolone per week for 6 weeks is most commonly used regimen. Cyclosporine 
can also be used either as a single therapy or in combination with oral prednisolone. 
Combination therapy of cyclosporine with prednisolone is more effective than either drug 
alone.55 
Orbital Radiotherapy 
Orbital radiotherapy is well tolerated and provide benefit in approximately two third of 
patients. This treatment is steroid sparing rather than steroid replacing therapy.  
Other immunomodulatory therapy 
Rituximab, azathioprine, cyclophosphamide, ciamexon, pentoxifylline and intravenous 
immunoglobulins have some benefit and are currently under trial. 
Orbital decompression 
Indications for orbital decompression include optic neuropathy, severe proptosis, vision 
threatening ocular exposure, debilitating retrobulbar and periorbital pain and intolerable 
corticosteroid side effects. Transantral orbital decompression with removal of a portion of 
medial wall and the orbital floor is most commonly used procedure. Upto 5 mm reduction 
in proptosis can be achieved by orbital decompression. Orbital decompression can cause 
onset or worsening of diplopia.  
Thyroid storm 
Thyroid storm or thyrotoxic crisis is a life threatening exacerbation of hyperthyroidism. 
Most of the cases of thyroid storm are associated with Graves' disease, but it can also occur 
with toxic multinodular goitre. Precipitating factor for thyroid storm include infection, 
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trauma, thyroid surgery, radioiodine, diabetic ketoacidosis, stroke etc. It can present with 
fever, tachycardia, arrhythmias, profuse sweating, diarrhea and vomiting, confusion, 
delirium, seizures, jaundice, coma, congestive heart failure, hypotension. Thyroid storm is 
associated with very high mortality rate (upto 30%, even with treatment).  
Treatment of thyroid storm requires strict monitoring and proper care. Precipitating factors 
should be identified and treated. Supportive treatment include cooling blankets and drugs 
like acetaminophen, chlorpromazine or meperidine for hyperthermia, oxygen inhalation, 
intravenous fluids. Antithyroid drug of choice is prophylthiouracil but carbimazole can also 
be used. Prophylthiouracil 600 mg is given as loading dose by mouth or nasogastric tube or 
per rectum followed by 200-300 mg every 6-8 hourly. One hour after the first dose of 
propylthiouracil, stable iodide is given in the form of SSKI (3 drops twice daily) or Lugol's 
iodine (10 drops twice daily). Propranolol should also be given in a dose of 40-80 mg orally 
every 6 hours or 2 mg intravenously every 4 hours. If β blockers are contraindicated, 
calcium channel blockers like diltiazem can be used to control tachycardia. Large dose of 
dexamethasone (8 mg) by oral or intravenous route should be given to block the release of 
hormone from gland and peripheral conversion of T4 to T3.  
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